曹林，南京诺唯赞生物科技股份有限公司创始人、董事长、总经理。南京大学博士
研究生毕业，中欧国际工商学院 EMBA。国家高层次人才特殊支持计划领军人才B类、 全国科技系统抗击新冠肺炎疫情先进个人、江苏省333工程培养对象、江苏省六大人才高峰高层次人才、江苏省“最美人物”、南京市“十大科技之星”、南京市有突出贡献中青年专家、南京市科技顶尖集聚计划专家、南京市“创新型企业家”、感动南京2020年人物。
其作为国家级人才重大工程专家，大力推动诺唯赞公司助力国家生物安全建设，部署加强生命科学领域的基础研究和医疗健康关键核心技术突破，加快提高疫病防控和公共卫生领域战略科技力量和战略储备能力。
其带领团队坚持从0到1的原始创新，始终以酶和蛋白质技术创新作为核心竞争力，一直致力打造体外诊断产品的核心原料；重大传染病、心脑血管、肿瘤等重大急、慢性疾病早期诊断试剂和检测设备；疫苗、新药研发等共性技术的创新能力。
公司在医疗诊断、生物医药核心关键领域攻坚多项高端酶、抗原抗体卡脖子技术，打破国际垄断。该领域现有200余种基因工程重组酶和1000余种高性能抗原和单克隆抗体等关键原料，拥有500多个终端产品，国内客户超过10000家，包括华大基因、药明康德、新希望等生物医药领域企业客户，在内资企业中市场份额排名第一。
在体外诊断试剂领域，公司在细菌病毒感染、心脑血管、优生优育、胃癌、肾功能、儿童呼吸道疾病等方面布局。
从2017年首次拿到产品注册证开始，至今已取得108项医疗器械注册证，现已是国内心肌标志物、感染标志物产品最齐全的企业之一。
系列产品在北京积水潭医院、北京肿瘤医院、军总医院、湘雅医院等2200家医院使用，其中三甲医院700余家。
2020年新冠病毒爆发，由于在之前爆发的非洲猪瘟和禽流感等公共卫生事件中积累了丰富的项目经验，曹林博士带领诺唯赞团队迅速投入研发工作，截止2022年底，累计提供核酸检测原料约34亿人份、新冠抗体检测试剂超5000万人份，新冠抗原检测试剂超3.5亿人份，此外还参与了国内头部疫苗企业的疫苗评价工作，承接临床CRO实验检测服务，以及支撑国内所有新冠疫苗技术路线的临床研究，同时研发出新冠抗体特效药并成功转让给国内知名药企，为疫情防控做出了重大贡献。
在他的带领下，诺唯赞公司已发展成为国家专精特新小巨人企业、中国独角兽企业，并于 2021年11月15在上海证券交易所科创板挂牌上市（证券代码：688105）。
Cao Lin is the Founder, Chairman and General Manager of Nanjing Vazyme Biotech Co., Ltd. He graduated with a doctoral degree from Nanjing University and obtained an EMBA from China Europe International Business School. His honourable mentions include high-level leading talent in China's high-level special support program, advanced individual in the fight against COVID-19, "Top Ten Science and Technology Stars" in Nanjing, young expert in Nanjing with outstanding contributions, expert in the Nanjing Science and Technology Top Talent Gathering Plan, "Innovative Entrepreneur" in Nanjing and individual touching Nanjing in 2020.
As the expert of China's national talent major project, Dr. Cao Lin has vigorously promoted Vazyme to help build China's biotechnology industry, deploy fundamental research in life sciences and breakthroughs key technology in health care and enhance prevention in disease control and public health.
Led by him, Vazyme has always taken innovation in enzyme and protein technology as core competitiveness and has been committing to provide core raw materials for IVD, develop early-stage diagnosis reagents and equipment for severe infectious diseases, cardiovascular diseases and tumors, as well as improving innovative capabilities of common technologies in vaccines and new drugs R&D.
Our products are applied in the diagnosis of major diseases such as COVID-19, cancer, and genetic abnormalities, as well as in the protection of public health such as African swine fever detection.
Vazyme has made breakthroughs and broken the international monopoly in several key areas of medical diagnosis and bio-pharmaceuticals, including high-end enzymes, antigens and antibodies. Currently, our product portfolio cover over 200 types of genetically engineered recombinant enzymes, over 1,000 types of high-performance antigens and monoclonal antibodies and more than 500 terminal products. Serving more than 10,000 business customers, including leading biopharmaceutical companies such as BGI Genomics, WuXi AppTec and New Hope Group, Vazyme ranks first in market share among Chinese domestic enterprises.
In the field of IVD reagents, Vazyme developed series of products for inflammation, cardiovascular diseases, reproductive health, gastric cancer, renal function and children's respiratory diseases.
Since receiving the first registration certificate in 2017, Vazyme has obtained 108 registration certificates for medical devices. And now has become one of the companies in China with the most complete product portfolio in intramyocardial markers and infection markers.
Our IVD products are widely used in 2,200 hospitals, including Peking Jishuitan Hospital, Beijing Cancer Hospital, PLA General Hospital and Xiangya Hospital, more than 700 of these are classified as 3A.
In the outbreak of COVID-19 in 2020, Dr. Cao Lin led the Vazyme team to promptly engage in R&D. Building on the wealth of project experience obtained from the public health issues like African swine fever and bird flu that occurred before, Vazyme has provided approximately 3.4 billion sets of nucleic acid detection raw materials, over 50 million sets of COVID-19 antibody detection reagents and over 350 million sets of COVID-19 antigen detection reagents by the end of 2022.
Furthermore, Vazyme has also participated in vaccine evaluation work for top domestic vaccine companies, undertaken clinical CRO experimental testing services, supported clinical research for all COVID-19 vaccine technology pathways in China and developed a COVID-19 antibody-specific drug that was successfully transferred to a well-known domestic pharmaceutical company and made significant contributions to epidemic prevention and control.
Under his leadership, Vazyme has grown into a national specialized and high-tech small giant enterprise, a Chinese unicorn enterprise and was quoted on the Shanghai Stock Exchange's Sci-Tech Innovation Board on November 15, 2021 (Stock Code: 688105).■
